Crossmark

Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study

Crossref DOI link: https://doi.org/10.1038/s41416-025-03285-x

Published Online: 2025-12-15

Published Print: 2026-02-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

He, Shui-Qing https://orcid.org/0000-0002-8873-0061
Huang, Ying https://orcid.org/0000-0002-8801-3660
Zhao, Ze-Yu https://orcid.org/0009-0002-1004-4464
Wen, Si-Qing

Lv, Shu-Hui

Wang, Lin https://orcid.org/0000-0002-9132-0805
Bei, Wei-Xin https://orcid.org/0009-0000-8726-3134
Xiang, Yan-Qun https://orcid.org/0000-0003-4334-3794
Liu, Guo-Ying https://orcid.org/0000-0002-1053-7050
License Information

Text and Data Mining valid from 2025-12-15

Version of Record valid from 2025-12-15
More Information

Article History

Received: 16 April 2025

Revised: 5 November 2025

Accepted: 14 November 2025

First Online: 15 December 2025

Competing interests

: The authors declare no competing interests.

: This retrospective study was approved by Sun Yat-sen University Cancer Center (SYSUCC, IRB-approved number, SL-B2024-371). All methods were performed in accordance with the relevant guidelines and regulations.

Document is current

Any future updates will be listed below